BFC Planning’s MiNK Therapeutics INKT Stock Holding History
Bought
Maintained
Sold
Other funds holding INKT
BS
BFC Planning's INKT Position: Q3 2026 in Review
BFC Planning sold out of MiNK Therapeutics (INKT) in Q3 2026, closing a stake of 2 shares — an estimated $23 sold.
BFC Planning first reported a position in INKT in Q2 2026 and held it in 1 quarter. The position peaked at $23 in Q2 2026. 22 funds tracked by Wall St. Rank hold INKT as of Q3 2026.
- BFC Planning reported no remaining MiNK Therapeutics position as of Q3 2026 after selling out during the quarter.
- BFC Planning sold 2 MiNK Therapeutics shares in Q3 2026, an estimated $23.
- BFC Planning first reported a position in MiNK Therapeutics in Q2 2026 and held it in 1 quarter.
- BFC Planning's MiNK Therapeutics position peaked at $23 in Q2 2026.
- 22 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.